HomeCirculationVol. 102, No. 22Multicenter Randomized Trial Comparing Amiodarone to Implantable Defibrillator in Patients With Nonischemic Cardiomyopathy and Asymptomatic Nonsustained Ventricular Tachycardia: AMIOVIRT Trial Free AccessOtherPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessOtherPDF/EPUBMulticenter Randomized Trial Comparing Amiodarone to Implantable Defibrillator in Patients With Nonischemic Cardiomyopathy and Asymptomatic Nonsustained Ventricular Tachycardia: AMIOVIRT Trial S. Adam Strickberger S. Adam StrickbergerS. Adam Strickberger for the AMIOVIRT Investigators. Search for more papers by this author Originally published28 Nov 2000https://doi.org/10.1161/01.CIR.102.22.2794Circulation. 2000;102:2794Introduction. Patients (pts) with nonischemic dilated cardiomyopathy (NIDCM) and asymptomatic (asx) nonsustained ventricular tachycardia (NSVT) are at high risk for sudden cardiac death. Amiodarone or an implantable defibrillator (ICD) may reduce mortality in this patient group. Therefore, the purpose of this multicenter, randomized trial was to compare the total mortality rate associated with amiodarone to ICD therapy in patients with NIDCM and asx NSVT. Methods. Pts with NIDCM, left ventricular ejection fraction < 0.35, and asx NSVT were eligible for study participation. 102 pts were randomized to receive either amiodarone or ICD therapy. 75 pts were followed in a study registry. Because there were no identifiable differences in clinical characteristics between randomized and registry pts, all pts were grouped according to initial therapy, irrespective of whether they were randomized or were followed in the study registry. The pts were 59±12 yrs, 29% were women, the left ventricular ejection fraction (LVEF) was 0.22±0.08, 85% had either NYHA Class II or III heart failure, and the mean follow-up was 20.1±12.6 months. The primary study endpoint was total mortality. The study was designed to achieve 80% power to identify a reduction in total mortality from 20% to 10% (219 patients in each group). Stopping rules included a mortality difference associated with a p < 0.025, or p ≥ 0.05 (90% power) when the data were extrapolated to 600 patients. Results. The stopping rule for futility was reached, and the study was stopped early. The percent of patients surviving at 2 years (88% vs 89%) and 4 years (85% vs 79%) in the amiodarone and ICD treatment groups, respectively, were similar (p=0.6). Conclusions. In pts with NIDCM, LVEF <0.35, and asx NSVT the total mortality rate at 4 years is the same in pts treated with Amiodarone or an ICD. Previous Back to top Next FiguresReferencesRelatedDetailsCited By Dimas V, Denfield S, Friedman R, Cannon B, Kim J, Smith E, Clunie S, Price J, Towbin J, Dreyer W and Kertesz N (2009) Frequency of Cardiac Death in Children With Idiopathic Dilated Cardiomyopathy, The American Journal of Cardiology, 10.1016/j.amjcard.2009.07.034, 104:11, (1574-1577), Online publication date: 1-Dec-2009. Fauchier L, Douglas J, Babuty D, Cosnay P and Fauchier J (2005) QT dispersion in nonischemic dilated cardiomyopathy. A long-term evaluation, European Journal of Heart Failure, 10.1016/j.ejheart.2004.07.009, 7:2, (277-282), Online publication date: 1-Mar-2005. Boriani G, Biffi M, Martignani C, Camanini C, Valzania C, Diemberger I, Saporito D, Bartolini P and Branzi A (2004) Cardiac Resynchronization Therapy: The Low Voltage Road or the High Voltage Road? Cardiac Arrhythmias 2003, 10.1007/978-88-470-2137-2_104, (785-791), . Hohnloser S, Klingenheben T, Bloomfield D, Dabbous O and Cohen R (2003) Usefulness of microvolt T-wave alternans for prediction of ventricular tachyarrhythmic events in patients with dilated cardiomyopathy: results from a prospective observational study, Journal of the American College of Cardiology, 10.1016/S0735-1097(03)00467-4, 41:12, (2220-2224), Online publication date: 1-Jun-2003. Exner D and Klein G (2003) Do We Need a Randomized Trial of Defibrillator Therapy in Every Subset of Patients with Increased Risk of Sudden Death?, Journal of Cardiovascular Electrophysiology, 10.1046/j.1540-8167.2003.03081.x, 14:6, (574-577), Online publication date: 1-Jun-2003. Boriani G, Biffi M, Martignani C, Camanini C, Grigioni F, Rapezzi C and Branzi A (2003) Cardioverter-defibrillators after MADIT-II: the balance between weight of evidence and treatment costs, European Journal of Heart Failure, 10.1016/S1388-9842(03)00099-0, 5:4, (419-425), Online publication date: 1-Aug-2003. Grimm W, Hoffmann J, Müller H and Maisch B (2002) Implantable defibrillator event rates in patients with idiopathic dilated cardiomyopathy, nonsustained ventricular tachycardia on Holter and a left ventricular ejection fraction below 30%, Journal of the American College of Cardiology, 10.1016/S0735-1097(01)01822-8, 39:5, (780-787), Online publication date: 1-Mar-2002. Stellbrink C, Sinha A, Diem B, Auricchio A, Boccanelli S, Brugada J, Klein H, Morgan J, Padeletti L, Aliot E and Hanrath P (2002) Implantable card ioverter-defibrillators with or without cardiac resynchronization therapy — multiple therapy in a single device: a review with special reference to the PACIVIAN study, European Heart Journal Supplements, 10.1093/ehjsupp/4.suppl_D.D88, 4:suppl_D, (D88-D94), Online publication date: 1-Apr-2002., Online publication date: 1-Apr-2002. Merino J (2001) Mechanisms Underlying Ventricular Arrhythmias in Idiopathic Dilated Cardiomyopathy, American Journal of Cardiovascular Drugs, 10.2165/00129784-200101020-00004, 1:2, (105-118), . Raj S and Sheldon R (2001) The implantable cardioverter-defibrillator, Progress in Cardiovascular Diseases, 10.1053/pcad.2001.29146, 44:3, (169-194), Online publication date: 1-Dec-2001. November 28, 2000Vol 102, Issue 22 Advertisement Article InformationMetrics Copyright © 2000 by American Heart Associationhttps://doi.org/10.1161/01.CIR.102.22.2794 Originally publishedNovember 28, 2000 PDF download Advertisement